A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis

Osteoarthritis and Cartilage

Volumn 21, Issue 2, 2013, Pages 289-297

  Hauber, A B ^a   Arden, N K ^b   Mohamed, A F ^a   Johnson, F R ^a   Peloso, P M ^c   Watson, D J ^c   Mavros, P ^c   Gammaitoni, A ^d   Sen, S S ^c   Taylor, S D ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Nuvo Research Inc   (United States)

Author keywords

Conjoint analysis; Discrete choice experiment; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Outcome assessment; Risk

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVERSE OUTCOME; AMBULATORY PAIN; ANALGESIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL DECISION MAKING; CONTROLLED STUDY; COOPERATION; DAILY LIFE ACTIVITY; DISCRETE CHOICE EXPERIMENT; DISEASE ASSOCIATION; FEMALE; GASTRIC ULCER BLEEDING; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT PREFERENCE; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; RESTING PAIN; RIGIDITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SELF REPORT; TASK PERFORMANCE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84872666170     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.11.007     Document Type: Article

References (45)

1. Arthritis Care The Impact of Arthritis (Statistics) http://www.arthritiscare.org.uk/@3235/Arthritisbasics/Arthritisstatistics/.
2. Jordan K.M., Sawyer S., Coakley P., Smith H.E., Cooper C., Arden N.K. The use of conventional and complementary treatments for knee osteoarthritis in the community. Rheumatology 2004, 43:381-384.
3. Porcheret M., Jordan K., Jinks C., Croft P. Primary care treatment of knee pain - a survey in older adults. Rheumatology 2007, 46:1694-1700.
4. Wolfe F., Zhao S., Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000, 43:378-385.
5. Merkle J., McDonald D. Use of recommended osteoarthritis pain treatment by older adults. J Adv Nurs 2009, 65:828-835.
6. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021-2029.
7. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
8. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Adenoma Prevention with Celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
9. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
10. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954-959.
11. Caldwell B., Aldington S., Weatherall M., Shirtcliffe P., Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006, 99:132-140.
12. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
13. Zhang J., Ding E.L., Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006, 296:1619-1632.
14. Fraenkel L., Wittink D.R., Concato J., Fried T. Informed choice and the widespread use of anti-inflammatory drugs. Arthritis Rheum 2004, 51:210-214.
15. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999, 56:18-24.
16. Katz J.N., Daltroy L.H., Brennan T.A., Liang M.H. Informed consent and the prescription of nonsteroidal antiinflammaory drugs. Arthritis Rheum 1992, 35:1257-1263.
17. Kopec J.A., Richardson C.G., Llewellyn-Thomas H., Klinkhoff A., Carswell A., Chalmers A. Probabilistic threshold technique showed that patients' preferences for specific trade-offs between pain relief and each side effect of treatment in osteoarthritis varied. J Clin Epidemiol 2007, 60:929-938.
18. Johnson F.R., Ozdemir S., Mansfield C., Hass S., Miller D.W., Siegel C.A., et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007, 133:769-779.
19. Johnson F.R., Van Houtven G., Özdemir S., Hass S., White J., Francis G. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol 2009, 256:554-562.
20. Hauber A.B., Johnson F.R., Grotzinger K., Özdemir S. Patients' benefit-risk preferences for chronic Idiopathic thrombocytopenic purpura (ITP) therapies. Ann Pharmacother 2010, 44:479-488.
21. Louviere J., Swait J., Hensher D. Introduction to stated preference models and methods. Stated Choice Methods: Analysis and Application 2000, 20-33. Cambridge University Press, Cambridge. J.J. Louviere, D.A. Hensher, J.D. Swait (Eds.).
22. Orme B.K. Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research 2006, Research Publishers LLC, Madison, WI.
23. Marshall D., Bridges J.F.P., Hauber A.B., Cameron R., Donnalley L., Fyie K., et al. Conjoint analysis applications in health - how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient 2010, 3:249-256.
24. Bridges J.F.P., Kinter E.T., Kidane L., Heinzen R.R., McCormick C. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. Patient 2008, 1:273-282.
25. Fraenkel L., Wittink D.R., Concato J., Fried T. Are preferences for cyclooxygenase-2 inhibitors influenced by the certainty effect?. J Rheumatol 2004, 31:591-593.
26. Fraenkel L., Bogardus S.T., Concato J., Wittink D.R. Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med 2004, 164:1299-1304.
27. Fraenkel L., Fried T. If you want patients with knee osteoarthritis (OA) to exercise: tell them about NSAIDs. Patient 2008, 1:21-26.
28. Ryan M., Gerard K. Discrete choice experiments. Assessing Quality of Life in Clinical Trials: Methods and Practice 2005, 431-445. Oxford University Press, Oxford. 2nd edn. P. Fayers, R. Hays (Eds.).
29. Ehrich E.W., Davies G.M., Watson D.J., Bolognese J.A., Seidenberg B.C., Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000, 27:2635-2641.
30. Bridges J.F.P., Hauber A.B., Marshall D., Lloyd A., Prosser L.A., Regier D.A., et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health 2011, 14:403-411.
31. Huber J., Zwerina K. The importance of utility balance in efficient choice designs. J Market Res 1996, 33:307-317.
32. Kanninen B. Optimal design for multinomial choice experiments. J Market Res 2002, 39:214-227.
33. Dey A. Orthogonal Fractional Factorial Designs 1985, Halstead Press, New York.
34. Kuhfeld W., Tobias F., Garratt M. Efficient experimental design with marketing research applications. J Market Res 1994, 31:545-557.
35. Zwerina K., Huber J., Kuhfeld W. A General Method for Constructing Efficient Choice Designs 1996, Fuqua School of Business, Duke University, Durham.
36. Train K. Discrete Choice Methods With Simulation 2003, Cambridge University Press, Cambridge, pp. 138-154.
37. Train K., Sonnier G. Mixed logit with bounded distributions of correlated partworths. Applications of Simulation Methods in Environmental and Resource Economics 2005, 117-134. Springer Publisher, Dordrecht. R. Scarpa, A. Alberini (Eds.).
38. Hensher D.A., Rose J.M., Greene W.H. Applied Choice Analysis 2005, Cambridge University Press, Cambridge.
39. Ratcliffe J., Buxton M., McGarry T., Sheldon R., Chancellor J. Patients' preferences for characteristics associated with treatments for osteoarthritis. Rheumatology 2004, 43:337-345.
40. Fraenkel L., Bogardus S.T., Concato J., Felson D.T., Wittink D.R. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004, 63:1372-1378.
41. Constantinescu F., Goucher S., Weinstein A., Smith W., Fraenkel L. Understanding why rheumatoid patient treatment preferences differ by race. Arthritis Rheum 2009, 61:413-418.
42. Özdemir S., Johnson F.R., Hauber A.B. Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ 2009, 28:894-901.
43. Perruccio A.V., Lohmander L.S., Canizares M., Tennant A., Hawker G.A., Conaghan P.G., et al. The development of a short measure of physical function for knee OA KOOS-Physical Function Shortform (KOOS-PS) - an OARSI/OMERACT initiative. Osteoarthritis Cartilage 2008, 16:542-550.
44. Rasooly I., Papageorgiou A.C., Badley E.M. Comparison of clinical and self reported diagnosis for rheumatology outpatients. Ann Rheum Dis 1995, 54:850-852.
45. Barlow J.H., Turner A.P., Wright C.C. Comparison of clinical and self-reported diagnoses for participants on a community-based arthritis self-management programme. Br J Rheumatol 1998, 37:985-987.